Femasys’ $34.45 Million IPO

Goodwin Procter advised the underwriters on the deal, while Dechert advised Femasys.

Chardan, a global investment bank, announced that it acted as lead left bookrunner in the successful closing of the $34.45 million IPO of Femasys, Inc. (NASDAQ: FEMY) a biomedical company focused on transforming women’s healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas.

Femasys is a woman-led company founded by Kathy Lee-Sepsick, President, CEO and Founder. Femasys will use the proceeds of their IPO to fund the completion of enrollment in the stage 2 clinical trial and commencement of the stage 3 clinical trial for the FemBloc system and for the initiation and completion of the pivotal trial for the FemaSeed system. The proceeds will also be used to fund product development and research and development activities, to hire additional personnel, and for working capital and general corporate purposes.

Chardan acted as lead left bookrunner for the offering. JonesTrading Institutional Services, LLC also acted as a bookrunner for the offering.

The Goodwin team was led by Thomas Levato (Picture), Kristopher Brown, Adi Vinyarsh, Kaitlin Carragher, and Stephanie Barbanell (Corporate), and included Julie Tibbets (FDA Regulatory); Delphine O’Rourke, Simone Otenaike, and Heath Ingram (Healthcare); Martin Gomez, Ken Radcliffe, Olivia Uitto, and Derek Denhart (Intellectual Property); Adam Romig and Leon Peschel (Tax); Grace Wirth (ERISA and Exec Comp); Tim Worden and Lucy Sharples (U.K. Regulatory); and Peter LaVigne (FINRA); with invaluable assistance from Nathan Needle.

Dechert advised Femasys with corporate partner David Rosenthal, and associates Anna Tomczyk and Christopher Polisano; employee benefits associate Jake Phillips; and tax partner Joshua Milgrim.

Involved fees earner: Joshua Milgrim – Dechert; Jake Phillips – Dechert; Chris Polisano – Dechert; David Rosenthal – Dechert; Anna Tomczyk – Dechert; Kristopher Brown – Goodwin Procter; Kaitlin Carragher – Goodwin Procter; Derek Denhart – Goodwin Procter; Martin Gomez – Goodwin Procter; Heath Ingram – Goodwin Procter; Peter LaVigne – Goodwin Procter; Thomas Levato – Goodwin Procter; Delphine O’Rourke – Goodwin Procter; Simone Otenaike – Goodwin Procter; Leon Peschel – Goodwin Procter; Kenneth Radcliffe – Goodwin Procter; Adam Romig – Goodwin Procter; Julie Tibbets – Goodwin Procter; Olivia Uitto – Goodwin Procter; Adi Vinyarsh – Goodwin Procter; Grace Wirth – Goodwin Procter; Tim Worden – Goodwin Procter;

Law Firms: Dechert; Goodwin Procter;

Clients: Chardan Capital Markets, LLC; Femasys; JonesTrading Institutional Services;

Martina Bellini

Author: Martina Bellini